Table 1 PD-L1 IHC and RNA-seq results for 209 samples
From: Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Test Result | Test | RCC | Melanoma | NSCLC |
|---|---|---|---|---|
≥1% TPS | IHC | 5 (11%) | 19 (25%) | 38 (43%) |
< 1% TPS | IHC | 40 (89%) | 57 (75%) | 50 (57%) |
≥50% TPS | IHC | NA | NA | 19 (22%) |
< 50% TPS | IHC | NA | NA | 69 (78%) |
≥1% ICS | IHC | 4 (9%) | NA | NA |
< 1% ICS | IHC | 41 (91%) | NA | NA |
> 75 rank (high) | RNA-seq | 9 (20%) | 11 (14%) | 35 (40%) |
25–75 rank (moderate) | RNA-seq | 24 (53%) | 39 (51%) | 42 (48%) |
> 25 rank (low) | RNA-seq | 12 (27%) | 26 (35%) | 11 (12%) |
Total | 45 | 76 | 88 |